Variables
|
Whole-cohort AML
|
Non-M3 AML
|
CN-AML
|
---|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
---|
SPAG1 expression
|
2.280 (1.562–3.327)
|
0.000
|
2.011 (1.366–2.962)
|
0.000
|
2.279 (1.283–4.047)
|
0.005
|
SPAG2/UAP1 expression
|
1.313 (0.908–1.897)
|
0.148
|
1.536 (1.052–2.241)
|
0.026
|
1.051 (0.614–1.798)
|
0.857
|
SPAG3/SPAG8 expression
|
0.901 (0.624–1.302)
|
0.578
|
1.021 (0.699–1.490)
|
0.914
|
0.801 (0.469–1.367)
|
0.416
|
SPAG4 expression
|
0.881 (0.610–1.273)
|
0.501
|
1.047 (0.718–1.527)
|
0.812
|
0.762 (0.442–1.315
|
0.329
|
SPAG5 expression
|
0.845 (0.584–1.223)
|
0.373
|
0.747 (0.509–1.096)
|
0.136
|
0.564 (0.319–0.998)
|
0.049
|
SPAG6 expression
|
1.504 (1.039–2.178)
|
0.031
|
1.359 (0.929–1.988)
|
0.114
|
0.990 (0.575–1.705)
|
0.971
|
SPAG7 expression
|
0.752 (0.519–1.089)
|
0.131
|
0.820 (0.560–1.202)
|
0.310
|
0.854 (0.498–1.467)
|
0.568
|
SPAG9 expression
|
0.986 (0.683–1.423)
|
0.939
|
0.906 (0.621–1.321)
|
0.607
|
1.176 (0.686–2.014)
|
0.556
|
SPAG10/MFGE8 expression
|
0.890 (0.616–1.287)
|
0.537
|
1.026 (0.703–1.498)
|
0.892
|
0.696 (0.406–1.193)
|
0.187
|
SPAG13/ITPRID2 expression
|
0.854 (0.591–1.234)
|
0.401
|
0.777 (0.532–1.134)
|
0.191
|
1.170 (0.683–2.004)
|
0.567
|
SPAG16 expression
|
1.427 (0.985–2.069)
|
0.060
|
1.257 (0.857–1.843)
|
0.242
|
1.320 (0.769–2.266)
|
0.314
|
SPAG17 expression
|
0.936 (0.648–1.351)
|
0.722
|
0.913 (0.626–1.332)
|
0.637
|
0.850 (0.498–1.453)
|
0.553
|
- AML: acute myeloid leukemia; CN-AML: cytogenetically normal AML; HR: hazard ratio; CI: confidence interval. The prognostic value of SPAG11A, SPAG11B, and SPAG16/SPAM1 expression was not determined because the three members were hardly expressed in AML patients